Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribociclib + trametinib
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Ribociclib + trametinib** is a combination of two small molecule targeted cancer therapies: ribociclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and trametinib, a MEK1/2 inhibitor. The mechanistic rationale is to simultaneously block cell cycle progression and mitogenic signaling, potentially providing synergistic antitumor effects. Ribociclib is developed and marketed under the brand name Kisqali by Novartis, and trametinib is developed and marketed as Mekinist by Novartis. This combination has been evaluated in clinical studies, including a Phase Ib trial in patients with metastatic or advanced solid tumors, with particular interest in advanced pancreatic adenocarcinoma and KRAS-mutant colorectal cancer. Clinical studies did not proceed to Phase II due to strategic reasons not related to safety[1][3][5]. Preclinical data also suggests potential utility in neuroendocrine tumors[4].
- Other names
- ribociclib + trametinibLEE011 + TMT212
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on ribociclib + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribociclib + trametinib.